[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635328":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":18,"responsibleParty":44,"collaborators":10,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":21,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Hospital Universitari de Bellvitge","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Elderly Mechanically Ventilated Patients (≥65 years)",null,"Critically ill patients aged 65 years or older requiring invasive mechanical ventilation for more than 48 hours. This is the primary study cohort in which innate immune immunoparalysis will be assessed and its association with ventilator-associated pneumonia will be analyzed.",{"label":13,"type":10,"description":14,"interventionNames":10},"Adult Mechanically Ventilated Patients (\u003C65 years)","Critically ill patients aged 18 to 64 years requiring invasive mechanical ventilation for more than 48 hours, included as a comparison cohort to evaluate age-related differences in immunoparalysis.",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy Non-Intubated Controls","Healthy adult volunteers without acute illness and not requiring mechanical ventilation. This group, assessed at a single time point, will serve as a reference population for baseline immunological parameters.",[19],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Servei de medicina intensiva, Hospital Universitari de Bellvitge","RECRUITING","L'Hospitalet de Llobregat","Barcelona","08907","Spain","ES",{"type":28,"coordinates":29},"Point",[30,31],2.10028,41.35967,{"lat":31,"lon":30},[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Joan Sabater Riera, MD, PhD","CONTACT","+34 932607646","jsabater@bellvitgehospital.cat",{"name":40,"role":36,"phone":41,"phoneExt":42,"email":43},"Arnau Ulsamer, PhD","+34 936073800","3068","aulsamer@idibell.cat",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Joan Sabater-Riera","Head of section","100635328","innate-immune-immunoparalysis-and-ventilator-associated-pneumonia-in-critically-ill-elderly-patients-100635328",false,"NCT07551258","Innate Immune Immunoparalysis and Ventilator-Associated Pneumonia in Critically Ill Elderly Patients","Intensity and Duration of Innate Immune System Immunoparalysis in the Pathophysiology of Ventilator-Associated Pneumonia in Mechanically Ventilated Elderly Patients","IMP-VM","Inclusion Criteria:\n\n* ≥18 years\n* Mechanical ventilation expected \\>48h\n* Intubation between 24h pre- and 48h post- ICU admission\n* Informed consent\n\nExclusion Criteria:\n\n* Known severe immunosuppression, including primary immunodeficiency disorders, advanced HIV infection (AIDS), active hematological malignancy under treatment, recent chemotherapy or immunosuppressive therapy\n* High dose steroids at immunosuppressive doses\n* Active autoimmune disease\n* Pregnancy\n* End-of-life situation",true,"ALL","18 Years",{"count":60,"type":61},170,"ESTIMATED","90 Days","OBSERVATIONAL","This prospective observational cohort study aims to evaluate the role of innate immune immunoparalysis in the development of ventilator-associated pneumonia (VAP) in critically ill mechanically ventilated patients. Immunoparalysis will be assessed through monocyte HLA-DR expression and ex vivo lipopolysaccharide (LPS)-stimulated TNF-α production.\n\nThe study will include three cohorts: elderly patients (≥65 years), younger adults (\\\u003C65 years), and healthy controls. The primary objective is to determine whether the presence, duration, intensity, and trend of immunoparalysis are associated with the incidence of VAP and other ICU-acquired infections. Secondary objectives include characterization of immunoparalysis dynamics, comparison of measurement methods, and evaluation of clinical outcomes.",[66,67,68],"Intubated ICU Patients","Ventilator Associated Pneumonia ( VAP)","Immunoparalysis",[70,71,72,73,74],"invasive mechanical ventilation","LPS stimulation","HLA-DR","innate immunity","ICU-acquired infections","2026-05-17",{"date":77,"type":78},"2026-05-19","ACTUAL",{"date":80,"type":61},"2026-05-01",{"date":82,"type":61},"2028-07-31",{"name":5,"class":6},1]